CN116637076A - 包含sGC刺激剂的固体分散体 - Google Patents

包含sGC刺激剂的固体分散体 Download PDF

Info

Publication number
CN116637076A
CN116637076A CN202310714716.7A CN202310714716A CN116637076A CN 116637076 A CN116637076 A CN 116637076A CN 202310714716 A CN202310714716 A CN 202310714716A CN 116637076 A CN116637076 A CN 116637076A
Authority
CN
China
Prior art keywords
compound
dispersion
solid dispersion
disease
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310714716.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·顿巴尔
V·塞瑟拉曼
A·哈沙什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclone Therapy Co ltd
Original Assignee
Cyclone Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclone Therapy Co ltd filed Critical Cyclone Therapy Co ltd
Publication of CN116637076A publication Critical patent/CN116637076A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202310714716.7A 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体 Pending CN116637076A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562260910P 2015-11-30 2015-11-30
US62/260,910 2015-11-30
US201662359440P 2016-07-07 2016-07-07
US62/359,440 2016-07-07
CN201680077389.7A CN108883071A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体
PCT/US2016/063312 WO2017095697A1 (en) 2015-11-30 2016-11-22 Solid dispersions comprising a sgc stimulator

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680077389.7A Division CN108883071A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体

Publications (1)

Publication Number Publication Date
CN116637076A true CN116637076A (zh) 2023-08-25

Family

ID=57590822

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202310714716.7A Pending CN116637076A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体
CN202310714714.8A Pending CN116942616A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体
CN202310714725.6A Pending CN116637077A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体
CN201680077389.7A Pending CN108883071A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202310714714.8A Pending CN116942616A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体
CN202310714725.6A Pending CN116637077A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体
CN201680077389.7A Pending CN108883071A (zh) 2015-11-30 2016-11-22 包含sGC刺激剂的固体分散体

Country Status (12)

Country Link
US (4) US20190269619A1 (https=)
EP (1) EP3383372B1 (https=)
JP (3) JP6952707B2 (https=)
KR (1) KR102841419B1 (https=)
CN (4) CN116637076A (https=)
AU (1) AU2016364976B2 (https=)
BR (1) BR112018011154B1 (https=)
CA (1) CA3006746C (https=)
EA (1) EA201891315A1 (https=)
IL (2) IL259493B (https=)
MX (3) MX389961B (https=)
WO (1) WO2017095697A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015718A2 (pt) 2016-02-01 2019-01-08 Ironwood Pharmaceuticals Inc utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
WO2018009602A2 (en) * 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Novel processes for preparation of soluble guanylate cyclase stimulators
WO2019055859A1 (en) 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
MA71753A (fr) * 2018-01-10 2025-05-30 Cyclerion Therapeutics, Inc. Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
WO2019172420A1 (ja) * 2018-03-09 2019-09-12 協和発酵キリン株式会社 医薬組成物
EP3829644A4 (en) * 2018-07-30 2022-05-04 Ricoh Company, Ltd. PROCESS FOR MANUFACTURING PARTICLES AND PARTICLE AND MEDICATION MANUFACTURED BY THE PROCESS
JP7503781B2 (ja) * 2018-07-30 2024-06-21 株式会社リコー 粒子の製造方法、並びに、それにより製造された粒子及び医薬
CA3149182A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
WO2021086967A1 (en) 2019-10-29 2021-05-06 Cyclerion Therapeutics, Inc. Treatment of diabetic nephropathy with an sgc stimulator
US20240000769A1 (en) * 2020-12-18 2024-01-04 UCB Biopharma SRL Amorphous solid dispersions
US20240366596A1 (en) 2021-07-28 2024-11-07 Cyclerion Therapeutics, Inc. Treatment of hfpef in post-menopausal women with an sgc stimulator

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207896A (zh) * 1997-08-11 1999-02-17 辉瑞产品公司 提高生物利用度的固体药物分散体
US20040013734A1 (en) * 1999-02-10 2004-01-22 Pfizer Inc. Pharmaceutical solid dispersions
CN103491964A (zh) * 2011-03-08 2014-01-01 扎里卡斯药品有限公司 固体分散体制剂及其使用方法
WO2014144100A2 (en) * 2013-03-15 2014-09-18 Takashi Nakai Sgc stimulators
US20150274712A1 (en) * 2012-09-18 2015-10-01 G-yoon Jamie Im sGC STIMULATORS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207896A (zh) * 1997-08-11 1999-02-17 辉瑞产品公司 提高生物利用度的固体药物分散体
US20040013734A1 (en) * 1999-02-10 2004-01-22 Pfizer Inc. Pharmaceutical solid dispersions
CN103491964A (zh) * 2011-03-08 2014-01-01 扎里卡斯药品有限公司 固体分散体制剂及其使用方法
US20150274712A1 (en) * 2012-09-18 2015-10-01 G-yoon Jamie Im sGC STIMULATORS
WO2014144100A2 (en) * 2013-03-15 2014-09-18 Takashi Nakai Sgc stimulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRIESEN D.T.等: "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", MOLECULAR PHARMACEUTICS, vol. 5, no. 6, 1 December 2008 (2008-12-01), pages 1003 - 1019 *

Also Published As

Publication number Publication date
AU2016364976A1 (en) 2018-06-14
JP6952707B2 (ja) 2021-10-20
IL290338A (en) 2022-04-01
JP2022000464A (ja) 2022-01-04
IL259493B (en) 2022-03-01
CA3006746C (en) 2024-01-30
JP7641320B2 (ja) 2025-03-06
JP2023100851A (ja) 2023-07-19
MX2022001655A (es) 2022-03-11
US20240293324A1 (en) 2024-09-05
IL290338B1 (en) 2023-01-01
MX2022001656A (es) 2022-03-11
JP2019501216A (ja) 2019-01-17
CN116942616A (zh) 2023-10-27
AU2016364976B2 (en) 2022-08-25
US20190269619A1 (en) 2019-09-05
MX389961B (es) 2025-03-20
CN108883071A (zh) 2018-11-23
WO2017095697A1 (en) 2017-06-08
US20250017862A1 (en) 2025-01-16
EA201891315A1 (ru) 2018-12-28
JP7277534B2 (ja) 2023-05-19
KR20180086497A (ko) 2018-07-31
CA3006746A1 (en) 2017-06-08
US20250255821A1 (en) 2025-08-14
EP3383372B1 (en) 2023-11-01
CN116637077A (zh) 2023-08-25
KR102841419B1 (ko) 2025-08-01
EP3383372A1 (en) 2018-10-10
BR112018011154A2 (pt) 2018-11-21
BR112018011154B1 (pt) 2023-09-26
IL259493A (en) 2018-07-31
IL290338B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
JP7641320B2 (ja) ｓＧＣ刺激薬を含んでなる固体分散剤
TWI810243B (zh) 用於治療囊腫纖化症之醫藥組合物
TWI719349B (zh) Ｃｆｔｒ調節劑之結晶形式及組合物
JP5017115B2 (ja) ４−（４−（３−（４−クロロ−３−トリフルオロメチルフェニル）ウレイド）−３−フルオロフェノキシ）ピリジン−２−カルボン酸を含んでなる過剰増殖性疾患の治療のための新規薬剤組成物
US20210228489A1 (en) Compositions for treating cystic fibrosis
KR102606253B1 (ko) 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
WO2020242935A1 (en) Methods of treatment for cystic fibrosis
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
US12318487B2 (en) Solid tablet dosage form of ridinilazole
KR102936624B1 (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
HK1261747A1 (en) Solid dispersions comprising a sgc stimulator
HK1261747B (en) Solid dispersions comprising a sgc stimulator
RU2822220C2 (ru) Фармацевтические композиции для лечения муковисцидоза
EA043018B1 (ru) Твердые дисперсии, содержащие стимулятор sgc, для применения в качестве лекарственного средства

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination